The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer.
 
Lauren Christine Harshman
No Relationships to Disclose
 
Xiaodong Wang
No Relationships to Disclose
 
Mari Nakabayashi
No Relationships to Disclose
 
Wanling Xie
No Relationships to Disclose
 
Loana Bueno Valenca
No Relationships to Disclose
 
Lillian Werner
No Relationships to Disclose
 
Yongjiang Yu
No Relationships to Disclose
 
Aaron Kantoff
Employment - Braeburn Pharmaceuticals
Stock and Other Ownership Interests - Tokai Pharmaceuticals
Other Relationship - Apple Tree Partners
 
Christopher Sweeney
Stock and Other Ownership Interests - Binding Site; Leuchemix
Consulting or Advisory Role - Astellas Pharma; Bayer; Binding Site; Janssen; Sanofi
Research Funding - Astellas Pharma; Exelixis
Patents, Royalties, Other Intellectual Property - Exelixis; Leuchemix
 
Lorelei A. Mucci
No Relationships to Disclose
 
Mark Pomerantz
No Relationships to Disclose
 
Gwo-Shu Mary Lee
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi